Agios Pharmaceuticals Shares Fall on FDA Review Extension

What happened

Agios Pharmaceuticals said the FDA extended the goal review date for its sickle cell disease drug mitapivat to Feb. 1, three months after the original date. The FDA requested more information before issuing the extension.

Confirmed

Global impact / market context

A longer FDA review delays possible approval and sales of mitapivat, so Agios keeps funding the program without new revenue from it. The 19% share drop shows investors see the delay as a setback despite unchanged safety claims.

Analyst inference

The FDA sought more information on whether a risk plan is needed and received about nine months of updated safety data before extending review. Agios says the drug's benefit-risk profile is unchanged, and the stock remains higher this year.

Analyst inference

What to watch

1. The FDA's new goal date is Feb. 1, three months after the original date for deciding on mitapivat. Confirmed
2. Agios says it will continue labeling discussions with the FDA during the ongoing review, which could shape eventual approval terms. Proposed
3. Watch whether the FDA decides a risk mitigation plan is needed, since that could add requirements before any approval. Analyst inference

Evidence

• Original source link unavailable